JP3278273B2
(ja)
*
|
1993-12-17 |
2002-04-30 |
キヤノン株式会社 |
薬剤徐放性カプセル
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
EP1365028B1
(en)
|
1996-12-13 |
2009-03-18 |
Novartis Vaccines and Diagnostics, Inc. |
Method for expression of PDGF or IGF proteins in yeast
|
US5985214A
(en)
|
1997-05-16 |
1999-11-16 |
Aurora Biosciences Corporation |
Systems and methods for rapidly identifying useful chemicals in liquid samples
|
JP4467789B2
(ja)
|
1997-09-18 |
2010-05-26 |
パシラ ファーマシューティカルズ インコーポレーテッド |
持続放出性リポソーム麻酔組成物
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
IL135989A0
(en)
|
1997-11-14 |
2001-05-20 |
Skyepharma Inc |
Processes for the production of multivesicular liposomes
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
CN101293920B
(zh)
|
1998-05-01 |
2012-07-18 |
诺华疫苗和诊断公司 |
脑膜炎奈瑟球菌抗原和组合物
|
EP1121437B1
(en)
|
1998-10-15 |
2008-02-20 |
Novartis Vaccines and Diagnostics, Inc. |
Metastatic breast and colon cancer regulated genes
|
AU2367600A
(en)
|
1998-12-16 |
2000-07-03 |
Chiron Corporation |
Human cyclin-dependent kinase ((hpnqalre))
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US20030008284A1
(en)
|
2000-06-15 |
2003-01-09 |
Giulia Kennedy |
Polynucleotides related to colon cancer
|
NZ530640A
(en)
|
1999-04-30 |
2006-06-30 |
Chiron S |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
AU784203B2
(en)
|
1999-10-29 |
2006-02-23 |
Glaxosmithkline Biologicals S.A. |
Neisserial antigenic peptides
|
ES2335386T3
(es)
|
1999-11-18 |
2010-03-26 |
Novartis Vaccines And Diagnostics, Inc. |
Gen fgf-21 humano y productos de expresion genica.
|
RU2279889C2
(ru)
|
2000-01-17 |
2006-07-20 |
Чирон С.Р.Л. |
ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
|
EP1261638A2
(en)
|
2000-03-08 |
2002-12-04 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
US7309783B2
(en)
|
2001-05-09 |
2007-12-18 |
The University Of Connecticut |
Mammalian early developmental regulator gene
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
AU2002359446B2
(en)
|
2001-11-09 |
2008-12-04 |
Georgetown University |
Novel isoforms of vascular endothelial cell growth inhibitor
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
EP1472375B1
(en)
|
2002-01-08 |
2009-04-01 |
Novartis Vaccines and Diagnostics, Inc. |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
US20040023267A1
(en)
|
2002-03-21 |
2004-02-05 |
Morris David W. |
Novel compositions and methods in cancer
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
WO2004058184A2
(en)
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
EP1594441B1
(en)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
GB2388581A
(en)
|
2003-08-22 |
2003-11-19 |
Danisco |
Coated aqueous beads
|
US20070104809A1
(en)
|
2003-08-22 |
2007-05-10 |
Danisco A/S |
Composition comprising a bacteriocin and an extract from a plant of the labiatae family
|
CA2551097A1
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
PL1732949T3
(pl)
|
2004-04-07 |
2010-06-30 |
Rinat Neuroscience Corp |
Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
|
EP1789593B1
(en)
|
2004-07-09 |
2017-03-15 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Soluble forms of hendra virus g glycoprotein
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
US7807165B2
(en)
|
2004-07-30 |
2010-10-05 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
RU2404750C2
(ru)
|
2004-11-23 |
2010-11-27 |
Адамас Фармасьютикалс, Инк. |
Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
WO2006058236A2
(en)
|
2004-11-24 |
2006-06-01 |
Neuromolecular Pharmaceuticals, Inc. |
Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
ES2385045T3
(es)
|
2005-02-18 |
2012-07-17 |
Novartis Vaccines And Diagnostics, Inc. |
Inmunógenos de Escherichia coli uropatogénica
|
CA2604052C
(en)
|
2005-04-06 |
2014-07-08 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cns-related conditions
|
US20090214536A1
(en)
|
2005-04-07 |
2009-08-27 |
Guoying Yu |
CACNA1E in Cancer Diagnosis, Detection and Treatment
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
EP1907425B1
(en)
|
2005-07-22 |
2014-01-08 |
Y's Therapeutics Co., Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
ES2664854T3
(es)
|
2005-11-14 |
2018-04-23 |
Teva Pharmaceuticals International Gmbh |
Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
|
CA2637707A1
(en)
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corporation |
Methods for treating obesity by administering a trkb antagonist
|
SG10201604649SA
(en)
|
2006-06-07 |
2016-07-28 |
Bioalliance Cv |
Antibodies Recognizing A Carbohydrate Containing Epitope On CD-43 And Cea Expressed On Cancer Cells And Methods Using Same
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
WO2008116032A1
(en)
|
2007-03-21 |
2008-09-25 |
Effat Emamian |
Compositions and methods for inhibiting tumor cell growth
|
EP2155777A2
(en)
|
2007-04-10 |
2010-02-24 |
The Administrators of the Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
KR101499278B1
(ko)
|
2007-12-17 |
2015-03-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
JP5568478B2
(ja)
|
2007-12-18 |
2014-08-06 |
バイオアライアンス セー.フェー. |
癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
|
US10000568B2
(en)
|
2008-04-10 |
2018-06-19 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
ES2662716T3
(es)
|
2009-07-07 |
2018-04-09 |
Glaxosmithkline Biologicals Sa |
Inmunógenos conservados de Escherichia coli
|
MX2012000734A
(es)
|
2009-07-16 |
2012-01-27 |
Novartis Ag |
Inmunogenos destoxificados de escherichia coli.
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
MX365650B
(es)
|
2009-12-02 |
2019-06-10 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
SA114360064B1
(ar)
|
2010-02-24 |
2016-01-05 |
رينات نيوروساينس كوربوريشن |
طرق وأجسام مضادة معارضة ضد مستقبل il-7
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
BR112012022917A2
(pt)
|
2010-03-11 |
2017-01-10 |
Pfizer |
anticorpos com ligação a antígeno dependente de ph
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9770414B2
(en)
*
|
2010-05-13 |
2017-09-26 |
Pacira Pharmaceuticals, Inc. |
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
BR112014011331A2
(pt)
|
2011-11-11 |
2017-04-25 |
Rinat Neuroscience Corp |
anticorpos específicos para trop-2 e seus usos
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
IN2014CN04652A
(he)
|
2011-12-22 |
2015-09-18 |
Rinat Neuroscience Corp |
|
US20150191702A1
(en)
|
2012-07-02 |
2015-07-09 |
Commonwealth Scientific And Industrial Research Organization |
Paramyxovirus and Methods of Use
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
CA2890483A1
(en)
|
2012-11-09 |
2014-05-15 |
Robert ARCH |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
CA2906624A1
(en)
|
2013-03-15 |
2014-09-25 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR102048718B1
(ko)
|
2013-08-02 |
2019-11-26 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
BR112016009797A2
(pt)
|
2013-11-13 |
2017-12-05 |
Bristol Myers Squibb Co |
anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
SI3119431T1
(sl)
|
2014-03-21 |
2024-06-28 |
Teva Pharmaceuticals International Gmbh |
Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
|
US10308697B2
(en)
|
2014-04-30 |
2019-06-04 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
PL3283106T3
(pl)
|
2015-04-13 |
2022-05-02 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
KR20180096567A
(ko)
|
2015-07-21 |
2018-08-29 |
다이액스 코포레이션 |
Xiia 인자의 단일클론 항체 저해제
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
PE20180556A1
(es)
|
2015-08-19 |
2018-04-02 |
Pfizer |
Anticuerpos inhibidores via del factor tisular y usos de los mismos
|
CN113896789A
(zh)
|
2015-09-15 |
2022-01-07 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
|
JP6661319B2
(ja)
*
|
2015-09-28 |
2020-03-11 |
小林製薬株式会社 |
リポソーム
|
EP3365369A1
(en)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
JP6902033B2
(ja)
|
2015-12-30 |
2021-07-14 |
アダマス ファーマシューティカルズ, インコーポレイテッド |
発作−関連障害の処置のための方法および組成物
|
WO2017125831A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
KR102069670B1
(ko)
*
|
2017-03-02 |
2020-01-23 |
단디바이오사이언스 주식회사 |
면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
|
JP2020510435A
(ja)
|
2017-03-03 |
2020-04-09 |
ライナット ニューロサイエンス コーポレイション |
抗gitr抗体およびその使用方法
|
EP3596206A1
(en)
|
2017-03-16 |
2020-01-22 |
Pfizer Inc |
Tyrosine prototrophy
|
EP3610010A4
(en)
|
2017-04-14 |
2021-02-24 |
Kodiak Sciences Inc. |
COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
|
WO2018200885A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Magnesium compositions and methods of use
|
US11421040B2
(en)
|
2017-06-02 |
2022-08-23 |
Pfizer Inc. |
Antibodies specific for FLT3 and their uses
|
KR102396784B1
(ko)
|
2017-06-13 |
2022-05-13 |
보스턴진 코포레이션 |
분자 기능적 프로파일을 생성하고, 시각화하고, 분류하는 시스템 및 방법
|
WO2019014418A1
(en)
|
2017-07-13 |
2019-01-17 |
Massachusetts Institute Of Technology |
TARGETING THE HDAC2-SP3 COMPLEX TO ENHANCE SYNAPTIC FUNCTION
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
KR20210027230A
(ko)
|
2017-10-04 |
2021-03-10 |
옵코 파마슈티칼스, 엘엘씨 |
암의 개인 맞춤형 치료에 관한 물품 및 방법
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
KR20200115596A
(ko)
|
2018-02-01 |
2020-10-07 |
화이자 인코포레이티드 |
Cd70에 특이적인 항체 및 이의 용도
|
SG11202007518RA
(en)
|
2018-02-28 |
2020-09-29 |
Pfizer |
Il-15 variants and uses thereof
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
SG11202010580TA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for cd3 and uses thereof
|
CN113286634A
(zh)
|
2018-05-23 |
2021-08-20 |
辉瑞公司 |
对gucy2c特异性的抗体及其用途
|
US20210005284A1
(en)
|
2019-07-03 |
2021-01-07 |
Bostongene Corporation |
Techniques for nucleic acid data quality control
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
CA3152623A1
(en)
|
2019-10-11 |
2021-04-15 |
Richard D. Cummings |
Anti-tn antibodies and uses thereof
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
WO2022023972A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
AU2021338361A1
(en)
|
2020-09-03 |
2023-04-06 |
Chen, Irvin S.Y |
Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
|
US20220180972A1
(en)
|
2020-12-04 |
2022-06-09 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
JP2024517745A
(ja)
|
2021-04-29 |
2024-04-23 |
ボストンジーン コーポレイション |
複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
AU2023213817A1
(en)
|
2022-01-31 |
2024-08-01 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|